Alumis Inc (ALMS) Stock Analysis
Verdict: WATCH (do not buy)
Clinical-stage TYK2 potential is high, but extreme valuation and 2025 cash burn (~$370M FCF) necessitate a wait for clinical de-risking.
Investment score: 48/100
Analysis as of
Is Alumis Inc stock worth reviewing? The TradeMates thesis
Alumis is a high-potential TYK2 play with strong analyst backing but faces a critical cash-burn vs. clinical-milestone race.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 70/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Alumis Inc opportunities and risks
What speaks for ALMS
- TYK2 Market Validation
What speaks against ALMS
- Accelerating Cash Burn
Frequently asked questions about Alumis Inc (ALMS)
Is ALMS stock a good investment?
The TradeMates model rates Alumis Inc as WATCH (do not buy) with an investment score of 48/100. Alumis is a high-potential TYK2 play with strong analyst backing but faces a critical cash-burn vs. clinical-milestone race. This is algorithmic model output, not personal investment advice.
Is ALMS stock a buy?
The TradeMates model verdict for ALMS is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.